Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Treasury Shares (2023 - 2025)

Historic Treasury Shares for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $774675.0.

  • Monte Rosa Therapeutics' Treasury Shares rose 59069.36% to $774675.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $774675.0, marking a year-over-year increase of 59069.36%. This contributed to the annual value of $112159.0 for FY2024, which is 5257.93% down from last year.
  • Monte Rosa Therapeutics' Treasury Shares amounted to $774675.0 in Q3 2025, which was up 59069.36% from $777325.0 recorded in Q2 2025.
  • Monte Rosa Therapeutics' Treasury Shares' 5-year high stood at $894334.0 during Q1 2025, with a 5-year trough of $91000.0 in Q1 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Treasury Shares value was $236519.0 (recorded in 2023), while the average stood at $357495.8.
  • Its Treasury Shares has fluctuated over the past 5 years, first plummeted by 5518.39% in 2024, then skyrocketed by 59069.36% in 2025.
  • Monte Rosa Therapeutics' Treasury Shares (Quarter) stood at $236519.0 in 2023, then crashed by 52.58% to $112159.0 in 2024, then soared by 590.69% to $774675.0 in 2025.
  • Its last three reported values are $774675.0 in Q3 2025, $777325.0 for Q2 2025, and $894334.0 during Q1 2025.